Loading...
Market
How will Chimerix's stock price move within a week of FDA decision by Q3 2025?
3
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Stock market data from financial platforms like Yahoo Finance or Bloomberg
Story
Chimerix Submits NDA for Dordaviprone to Treat Recurrent H3 K27M-Mutant Diffuse Glioma, Expects FDA Decision by Q3 2025
Dec 30, 2024, 08:37 PM
Chimerix, Inc. has submitted a New Drug Application (NDA) for accelerated approval of its drug, dordaviprone, to the U.S. Food and Drug Administration (FDA). The drug targets patients with recurrent H3 K27M-mutant diffuse glioma, a type of brain tumor. The FDA is expected to make a decision by the third quarter of 2025. In conjunction with the NDA submission, Chimerix entered into a credit facility of up to $30 million with Silicon Valley Bank, which will provide additional capital to ensure the availability of dordaviprone to patients, should it receive approval. The company is backed by major advocate groups focused on pediatric patients affected by this condition.
View original story
Similar markets
No significant change • 25%
Underperforms biotech index • 25%
Performs in line with biotech index • 25%
Outperforms biotech index • 25%
$100 million to $200 million • 25%
Below $100 million • 25%
Above $300 million • 25%
$200 million to $300 million • 25%
Decrease by 10% or more • 25%
Increase by 10% or more • 25%
Decrease by less than 10% • 25%
Increase by less than 10% • 25%
Increase over 20% • 25%
Decrease • 25%
No change • 25%
Increase 0-20% • 25%
No significant change or decrease • 25%
Increase by less than 5% • 25%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
Decrease by over 10% • 25%
Increase by over 10% • 25%
Decrease by less than 10% • 25%
Increase by less than 10% • 25%
Yes • 50%
No • 50%
